Background: Hepatitis B Virus (HBV) transmission in India is presumed predominantly horizontal, but there is scanty data. We conducted this study to test the hypothesis that chronic HBV (CHB) infection in India is predominantly due to perinatal transmission. Aim: To determine the source of acquisition of HBV infection in CHB patients. Patients and Methods: Consecutive patients presenting with CHB whose relatives consented for evaluation were enrolled and tested for HBsAg, anti-HBe, anti-HBs and total anti-HBc. Vertical transmission was defined when the mother was HBsAg positive or total anti-HBc positive and/or anti-HBe (suggestive of past exposure). 254 controls were also recruited for comparison. 
PP-088 Asymptomatic carriers and chronic hepatitis B antiviral therapy and efficacy with non-specific immune activation of the relationship between the drug applications
Zu-liang Han *, Yu-sheng Sun, Xin-qi Li. Huang Pu People's Hospital, Zhongshan, Guangdong Objective: To antiviral drugs alone applications and with nonspecific immune activation of the drug combination treatment, and explore hepatitis B and chronic hepatitis B virus carriers with non-specific immune relationship. Methods: 255 cases of HBeAg-positive and-negative asymptomatic carriers and chronic hepatitis B were randomly divided into 2 groups; observation of lamivudine and Mycobacterium FU36 with Chinese medicine group (A group), lamivudine and Chinese medicine group (B group), HBV-DNA on the efficacy, safety and efficacy issues, treatment 3 months, 9 month follow-up. Conclusions: Drug alone and combined application of emerging HBV-DNA the reasons for differences in efficacy, and HBV-DNA and non-specific immune response there is existence of "equivalence" relations, and further the formation of each other "impact" or "constraints" relationship, as well as the efficacy of existence there is the "dependency" or "complementary relationship" there is close relationship.
PP-090 Asymptomatic carriers to obtain HBV-DNA efficacy and drug applications and selectthe relationship between treatment modalities
Zu-liang Han *, Yu-sheng Sun, Yin-xiang Liu, Xin-qi Li, Jia-rui Wang. Huang Pu People's Hospital,Zhongshan,Guangdong
Purpose: Observation of asymptomatic carriers negative HBV-DNA to obtain the efficacy of the combination drug, the relationship between forms of treatment. Methods: to 304 cases of asymptomatic carriers were randomly divided into a treatment group and 4 control group; Lamivudine and the Chinese medicines group (A), lamivudine and Mycobacterium FU36 and the Chinese medicines group (B), Mycobacterium FU36 and the Chinese medicines group (C), Mycobacterium FU 36 and demethylcantharidin tablets with Chinese medicine group (D), and group B and D turn of the application of group (treatment group), observation periods of different treatment on liver function, HBeAg, and HBV-DNA target, such as the effects of 6-month course of treatment, follow-up 6 months. Results: 1) HBeAg-positive carriers of asymptomatic, treatment group has 71.87% and 65.62% have access to HBV-DNA negative and seroconversion HbeAg efficacy, significantly higher than that of the efficacy of other groups, P <0.01; 2) HBeAg-negative carriers of asymptomatic, B group and treatment group were 93.10% and79.31% was HBV-DNA negative efficacy, significantly higher than the effect of the other 3 groups, P <0.01, there is no adverse reaction. Conclusion: Low non-specific immune response, HBV-DNA, HBeAg, as well as specific immune tolerance to affect the existence of the cross, as well as the complementary relationship between efficacy, the formation of the HBeAg-positive and-negative asymptomatic carriers to obtain HBV-DNA negative effect of the treatment process and treatment of existence of the way there is a significant difference.
